• Je něco špatně v tomto záznamu ?

Colorectal Tumour Mucosa Microbiome Is Enriched in Oral Pathogens and Defines Three Subtypes That Correlate with Markers of Tumour Progression

B. Zwinsová, VA. Petrov, M. Hrivňáková, S. Smatana, L. Micenková, N. Kazdová, V. Popovici, R. Hrstka, R. Šefr, B. Bencsiková, L. Zdražilová-Dubská, V. Brychtová, R. Nenutil, P. Vídeňská, E. Budinská

. 2021 ; 13 (19) : . [pub] 20210925

Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc22001690

Grantová podpora
AZV 16-31966A Ministerstvo Zdravotnictví Ceské Republiky
825410 Horizon 2020 Framework Programme

Long-term dysbiosis of the gut microbiome has a significant impact on colorectal cancer (CRC) progression and explains part of the observed heterogeneity of the disease. Even though the shifts in gut microbiome in the normal-adenoma-carcinoma sequence were described, the landscape of the microbiome within CRC and its associations with clinical variables remain under-explored. We performed 16S rRNA gene sequencing of paired tumour tissue, adjacent visually normal mucosa and stool swabs of 178 patients with stage 0-IV CRC to describe the tumour microbiome and its association with clinical variables. We identified new genera associated either with CRC tumour mucosa or CRC in general. The tumour mucosa was dominated by genera belonging to oral pathogens. Based on the tumour microbiome, we stratified CRC patients into three subtypes, significantly associated with prognostic factors such as tumour grade, sidedness and TNM staging, BRAF mutation and MSI status. We found that the CRC microbiome is strongly correlated with the grade, location and stage, but these associations are dependent on the microbial environment. Our study opens new research avenues in the microbiome CRC biomarker detection of disease progression while identifying its limitations, suggesting the need for combining several sampling sites (e.g., stool and tumour swabs).

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22001690
003      
CZ-PrNML
005      
20220112153659.0
007      
ta
008      
220107s2021 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/cancers13194799 $2 doi
035    __
$a (PubMed)34638284
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Zwinsová, Barbora $u Research Centre for Applied Molecular Oncology (RECAMO), Masaryk Memorial Cancer Institute, 656 53 Brno, Czech Republic $u Research Centre for Toxic Compounds in the Environment (RECETOX), Faculty of Science, Masaryk University, 625 00 Brno, Czech Republic $u Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, 625 00 Brno, Czech Republic
245    10
$a Colorectal Tumour Mucosa Microbiome Is Enriched in Oral Pathogens and Defines Three Subtypes That Correlate with Markers of Tumour Progression / $c B. Zwinsová, VA. Petrov, M. Hrivňáková, S. Smatana, L. Micenková, N. Kazdová, V. Popovici, R. Hrstka, R. Šefr, B. Bencsiková, L. Zdražilová-Dubská, V. Brychtová, R. Nenutil, P. Vídeňská, E. Budinská
520    9_
$a Long-term dysbiosis of the gut microbiome has a significant impact on colorectal cancer (CRC) progression and explains part of the observed heterogeneity of the disease. Even though the shifts in gut microbiome in the normal-adenoma-carcinoma sequence were described, the landscape of the microbiome within CRC and its associations with clinical variables remain under-explored. We performed 16S rRNA gene sequencing of paired tumour tissue, adjacent visually normal mucosa and stool swabs of 178 patients with stage 0-IV CRC to describe the tumour microbiome and its association with clinical variables. We identified new genera associated either with CRC tumour mucosa or CRC in general. The tumour mucosa was dominated by genera belonging to oral pathogens. Based on the tumour microbiome, we stratified CRC patients into three subtypes, significantly associated with prognostic factors such as tumour grade, sidedness and TNM staging, BRAF mutation and MSI status. We found that the CRC microbiome is strongly correlated with the grade, location and stage, but these associations are dependent on the microbial environment. Our study opens new research avenues in the microbiome CRC biomarker detection of disease progression while identifying its limitations, suggesting the need for combining several sampling sites (e.g., stool and tumour swabs).
655    _2
$a časopisecké články $7 D016428
700    1_
$a Petrov, Vyacheslav A $u Research Centre for Toxic Compounds in the Environment (RECETOX), Faculty of Science, Masaryk University, 625 00 Brno, Czech Republic
700    1_
$a Hrivňáková, Martina $u Research Centre for Applied Molecular Oncology (RECAMO), Masaryk Memorial Cancer Institute, 656 53 Brno, Czech Republic $u Research Centre for Toxic Compounds in the Environment (RECETOX), Faculty of Science, Masaryk University, 625 00 Brno, Czech Republic
700    1_
$a Smatana, Stanislav $u Research Centre for Toxic Compounds in the Environment (RECETOX), Faculty of Science, Masaryk University, 625 00 Brno, Czech Republic $u Research Centre of Information Technology, IT4Innovations Centre of Excellence, Brno University of Technology, 601 90 Brno, Czech Republic
700    1_
$a Micenková, Lenka $u Research Centre for Toxic Compounds in the Environment (RECETOX), Faculty of Science, Masaryk University, 625 00 Brno, Czech Republic
700    1_
$a Kazdová, Natálie $u Research Centre for Toxic Compounds in the Environment (RECETOX), Faculty of Science, Masaryk University, 625 00 Brno, Czech Republic
700    1_
$a Popovici, Vlad $u Research Centre for Toxic Compounds in the Environment (RECETOX), Faculty of Science, Masaryk University, 625 00 Brno, Czech Republic
700    1_
$a Hrstka, Roman $u Research Centre for Applied Molecular Oncology (RECAMO), Masaryk Memorial Cancer Institute, 656 53 Brno, Czech Republic
700    1_
$a Šefr, Roman $u Research Centre for Applied Molecular Oncology (RECAMO), Masaryk Memorial Cancer Institute, 656 53 Brno, Czech Republic
700    1_
$a Bencsiková, Beatrix $u Research Centre for Applied Molecular Oncology (RECAMO), Masaryk Memorial Cancer Institute, 656 53 Brno, Czech Republic
700    1_
$a Zdražilová-Dubská, Lenka $u Department of Pharmacology, Faculty of Medicine, Masaryk University, 625 00 Brno, Czech Republic $u Department of Laboratory Medicine-Clinical Microbiology and Immunology, University Hospital Brno, 625 00 Brno, Czech Republic
700    1_
$a Brychtová, Veronika $u Research Centre for Applied Molecular Oncology (RECAMO), Masaryk Memorial Cancer Institute, 656 53 Brno, Czech Republic
700    1_
$a Nenutil, Rudolf $u Research Centre for Applied Molecular Oncology (RECAMO), Masaryk Memorial Cancer Institute, 656 53 Brno, Czech Republic
700    1_
$a Vídeňská, Petra $u Research Centre for Applied Molecular Oncology (RECAMO), Masaryk Memorial Cancer Institute, 656 53 Brno, Czech Republic $u Research Centre for Toxic Compounds in the Environment (RECETOX), Faculty of Science, Masaryk University, 625 00 Brno, Czech Republic
700    1_
$a Budinská, Eva $u Research Centre for Applied Molecular Oncology (RECAMO), Masaryk Memorial Cancer Institute, 656 53 Brno, Czech Republic $u Research Centre for Toxic Compounds in the Environment (RECETOX), Faculty of Science, Masaryk University, 625 00 Brno, Czech Republic
773    0_
$w MED00173178 $t Cancers $x 2072-6694 $g Roč. 13, č. 19 (2021)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/34638284 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20220107 $b ABA008
991    __
$a 20220112153655 $b ABA008
999    __
$a ind $b bmc $g 1745575 $s 1152837
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 13 $c 19 $e 20210925 $i 2072-6694 $m Cancers $n Cancers $x MED00173178
GRA    __
$a AZV 16-31966A $p Ministerstvo Zdravotnictví Ceské Republiky
GRA    __
$a 825410 $p Horizon 2020 Framework Programme
LZP    __
$a Pubmed-20220107

Najít záznam

Citační ukazatele

Možnosti archivace